Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19

A SARS-CoV receptor-binding domain (RBD) recombinant protein was developed and manufactured under current good manufacturing practices in 2016. The protein, known as RBD219-N1 when formulated on Alhydrogel®, induced high-level neutralizing antibodies and protective immunity with minimal immunopathol...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wen-Hsiang, Hotez, Peter J., Bottazzi, Maria Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482854/
https://www.ncbi.nlm.nih.gov/pubmed/32298218
http://dx.doi.org/10.1080/21645515.2020.1740560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482854/
https://www.ncbi.nlm.nih.gov/pubmed/32298218
http://dx.doi.org/10.1080/21645515.2020.1740560

Ejemplares similares